|
|
|
21.11.25 - 03:57
|
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional 10,344,827 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Inhibikase ...
|
|
|
21.11.25 - 03:03
|
The North West Company Inc. Announces Renewal of its Normal Course Issuer Bid (GlobeNewswire EN)
|
|
|
WINNIPEG, Manitoba, Nov. 20, 2025 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the “Company” or “North West”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted notice of the Company's intention to make a normal course issuer bid (“NCIB”) for a portion of its common voting shares and variable voting shares (the “Shares”) as appropriate opportunities arise from time to time. The board of directors of the Company believes that the purchase by the Company of a portion of its outstanding Shares may from time to time be an appropriate use of available resources and in the best interests of the Company....
|
|
|
21.11.25 - 03:03
|
GAC Accelerates European EV Strategy with Magna Vehicle Assembly Program (GlobeNewswire EN)
|
|
|
GUANGZHOU, China and AURORA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Today, GAC and Magna announced a vehicle assembly program to accelerate electric mobility and expand localized EV production in Europe. The collaboration underscores GAC's regional commitment, extending assembly, supply and sales, while highlighting Magna's leadership in vehicle manufacturing. Serial production of GAC's electric SUV AION V is now underway at Magna's Graz facility....
|
|
|
|
|
21.11.25 - 02:03
|
NovaBridge′s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has appointed Cadmus C. Rich, MD, MBA, as its Chief Medical Officer (CMO), and Carlos Quezada-Ruiz MD, FASRS, as Chairman of its Scientific Advisory Board (SAB). As CMO, Dr. Rich will be responsible for overseeing all of the clinical functions and programs for Visara. Dr. Quezada-Ruiz will chair Visara's newly formed SAB....
|
|
|
|
|
|
|
|
|
21.11.25 - 00:36
|
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs....
|
|
|
21.11.25 - 00:24
|
Faraday Future Completes Formation of “FFAI+AIXC” Dual-Flywheel, Dual-Bridge, and Dual-Listed Company System; Its Majority Owned Crypto Company Renamed as AIxCrypto (Nasdaq: AIXC) (GlobeNewswire EN)
|
|
|
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that its majority-owned Nasdaq-listed company, Qualigen Therapeutics Inc., completed its name and ticker change to AIxCrypto Holdings Inc. (“AIxC”) and “AIXC,” respectively. This represents an important step in advancing the “FFAI + AIXC” dual-flywheel, dual-bridge, and dual-listed company framework and supports the ongoing development of EAI + Crypto initiatives aimed at bridging Web2 and Web3....
|
|
|
|
|
|
|
20.11.25 - 23:30
|
BioSyent Declares Fourth Quarter 2025 Dividend (GlobeNewswire EN)
|
|
|
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors....
|
|
|
20.11.25 - 23:27
|
J & J SNACK FOODS CORP. ANNOUNCES QUARTERLY CASH DIVIDEND (GlobeNewswire EN)
|
|
|
MOUNT LAUREL, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- J & J Snack Foods Corp. (Nasdaq: JJSF) announced today that its Board of Directors has declared a quarterly cash dividend of $0.80 per share of its common stock payable on January 6, 2026, to shareholders of record as of the close of business on December 16, 2025....
|
|
|
|
|
20.11.25 - 23:09
|
Regional Health Properties Reports Third Quarter 2025 Results Following Completion of Merger with SunLink Health Systems, Inc. (GlobeNewswire EN)
|
|
|
ATLANTA, GA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB:RHEPZ), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, today announced its financial results for the third quarter ended September 30, 2025....
|
|
|
20.11.25 - 23:09
|
RWA Ecosystem Grows Stronger: OFA Group Confirms the Hearth Labs RWA Platform Is on Track for Full Deployment, Powering a New Era of Real-World Asset Tokenization (GlobeNewswire EN)
|
|
|
Los Angeles, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- OFA Group (NASDAQ: OFAL) announced today that development of its real-world-asset (RWA) platform, Hearth, created by its wholly owned subsidiary Hearth Labs, Inc., remains on schedule for a full release by late 2025 or early Q1 2026. Hearth is designed as a unified, blockchain-native infrastructure system that allows qualified real estate and other income-producing assets to be validated, structured, tokenized, and managed on-chain. The platform integrates valuation tools, verification workflows, and ongoing reporting to create a transparent and standardized environment for tokenizing real-world assets....
|
|
|
|
|
20.11.25 - 23:03
|
Skyharbour Engages Emerging Markets Consulting LLC for Marketing Contract (GlobeNewswire EN)
|
|
|
Vancouver, BC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour”, “SYH” or the “Company”) is pleased to announce that it has engaged Emerging Markets Consulting, LLC (“EMC”), for a 12-month marketing and investor awareness campaign, commencing on November 20th, 2025, for a upfront, non-refundable fee of USD $200,000. Pursuant to an agreement dated November 20th, 2025, EMC will assist the Company with the design, development, and dissemination of approved corporate information, as well as general investor outreach activities conducted through its internal marketing channels and broker-focused networks. Services under the agreement may include electronic media and webcast support, drafting or assembling approved corporate materials, distribution through EMC's email databases, and communications with brokers and institutions selected by EMC. The engagement of Emerging Markets Consulting remains subject to the approval ...
|
|
|
|